Ligand ID: TOY


Drugbank ID:
DB00684
(Tobramycin)


Indication:
For the treatment of pseudomonas aeruginosa lung infections. Also being investigated for use in the treatment of sinus infections.

Get human targets for TOY in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'TOY' AND SARS-COV-2 / COVID-19 STRUCTURES

1) User may click on the DrReposER ID (the first column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera throuh AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASP A 235
TYR A 238
ILE A 466
TYR A 294
1.77A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6m71 NSP12
(SARS-CoV-2)		5 / 10
SER A 564
SER A 561
ALA A 502
ASP A 684
THR A 565
1.60A11.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_B_TOYB501_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6m71 NSP12
(SARS-CoV-2)		5 / 9
SER A 564
SER A 561
ALA A 502
ASP A 684
THR A 565
1.58A11.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASP A 155
ASP A 153
ASP A 154
TYR A 149
1.71A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASP A 481
ASP A 477
GLU A 474
ASP A 304
1.73A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASP A 481
ASP A 477
GLU A 474
ASP A 304
1.76A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ASP A  40
TYR A 204
ILE A 197
ASP A  53
1.11A8.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ASP A  40
TYR A 204
ILE A 197
ASP A  53
1.06A8.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6vsb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
GLU A1092
SER C1123
ALA C1087
THR C1120
ASP A1118
1.63A9.06
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ASP C  40
TYR C 204
ILE C 197
ASP C  53
1.32A8.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6vxx SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ASP C  40
TYR C 204
ILE C 197
ASP C  53
1.30A8.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EVY_B_TOYB201_1
(AMINOGLYCOSIDE
N(6')-ACETYLTRANSFER
ASE TYPE 1)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 10
TYR A 396
ASN A 394
GLU A 516
ARG A 466
GLY B 232
1.64A9.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EVY_A_TOYA201_1
(AMINOGLYCOSIDE
N(6')-ACETYLTRANSFER
ASE TYPE 1)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		5 / 9
ARG A 466
GLY B 232
TYR A 396
ASN A 394
GLU A 516
1.70A9.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ASP C  40
TYR C 204
ILE C 197
ASP C  53
1.32A8.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6vyb SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ASP C  40
TYR C 204
ILE C 197
ASP C  53
1.39A8.92
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6w41 CR3022 FAB LIGHT
CHAIN
SPIKE PROTEIN S1
(Homo
sapiens;
SARS-CoV-2)		5 / 9
PHE C 429
ASP C 428
ILE L  28
SER C 514
VAL C 512
1.77A16.59
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EVY_B_TOYB201_1
(AMINOGLYCOSIDE
N(6')-ACETYLTRANSFER
ASE TYPE 1)		6w4h NSP16
(SARS-CoV-2)		5 / 10
ASN A6975
GLU A6945
ASP A6912
GLY A6953
ASP A6977
1.71A18.73
None
None
SAM  A7102 (-3.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6w4h NSP16
(SARS-CoV-2)		5 / 10
PHE A6947
SER A6927
ALA A6966
ASP A6895
ASP A6897
1.73A20.25
ACT  A7104 (-3.8A)
None
None
None
SAM  A7102 (-2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EVY_B_TOYB201_1
(AMINOGLYCOSIDE
N(6')-ACETYLTRANSFER
ASE TYPE 1)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 10
ASN A6975
GLU A6945
ASP A6912
GLY A6953
ASP A6977
1.68A22.41
None
None
SAM  A7104 (-3.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6w61 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 10
PHE A6947
SER A6927
ALA A6966
ASP A6895
ASP A6897
1.73A
EDO  A7102 (-3.8A)
None
None
None
SAM  A7104 (-2.8A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6w75 NSP16
(SARS-CoV-2)		4 / 8
TYR C7020
ASP C6942
ILE C7027
TYR C6979
1.54A22.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6w75 NSP16
(SARS-CoV-2)		5 / 10
PHE C6947
SER C6927
ALA C6966
ASP C6895
ASP C6897
1.74A20.90
FMT  C7115 ( 3.5A)
None
None
None
SAM  C7105 ( 2.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6w75 NSP16
(SARS-CoV-2)		4 / 8
ASP A6931
GLU A6945
ASP A6942
TYR A7020
1.74A22.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6w75 NSP16
(SARS-CoV-2)		5 / 10
PHE A6947
SER A6927
ALA A6966
ASP A6895
ASP A6897
1.72A20.90
SAM  A7102 ( 4.8A)
None
None
None
SAM  A7102 ( 2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6w75 NSP16
(SARS-CoV-2)		4 / 8
TYR C7020
ASP C6942
ILE C7027
TYR C6979
1.58A22.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 10
PHE A6947
SER A6927
ALA A6966
ASP A6895
ASP A6897
1.73A
SAH  A7102 (-4.7A)
None
None
None
SAH  A7102 (-2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ASP A6931
GLU A6945
ASP A6942
TYR A7020
1.72A21.82
None
FMT  A7108 (-3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 10
PHE C6947
SER C6927
ALA C6966
ASP C6895
ASP C6897
1.75A
SAH  C7102 (-4.6A)
None
None
None
SAH  C7102 (-2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6wjt 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		4 / 8
ASP A6931
GLU A6945
ASP A6942
TYR A7020
1.80A21.82
None
FMT  A7108 (-3.8A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6wkq NSP16
(SARS-CoV-2)		5 / 10
PHE C6947
SER C6927
ALA C6966
ASP C6895
ASP C6897
1.74A
FMT  C7105 ( 3.5A)
None
None
None
SFG  C7103 ( 2.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6wkq NSP16
(SARS-CoV-2)		5 / 10
PHE A6947
SER A6927
ALA A6966
ASP A6895
ASP A6897
1.72A
SFG  A7103 ( 4.8A)
None
None
None
SFG  A7103 ( 2.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		5 / 9
PHE A 195
SER A 155
VAL A 156
GLU A 327
GLU A 192
1.53A22.52
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP B 302
GLU B 211
ILE B 253
TYR B 226
1.67A20.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP A 302
GLU A 211
ILE A 253
TYR A 226
1.79A20.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP A 302
GLU A 211
ILE A 253
TYR A 226
1.65A20.28
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EVY_B_TOYB201_1
(AMINOGLYCOSIDE
N(6')-ACETYLTRANSFER
ASE TYPE 1)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 10
ASN A6975
GLU A6945
ASP A6912
GLY A6953
ASP A6977
1.65A
None
None
SAH  A7101 (-3.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		6wq3 2'-O-METHYLTRANSFERA
SE
(SARS-CoV-2)		5 / 10
PHE A6947
SER A6927
ALA A6966
ASP A6895
ASP A6897
1.74A
SAH  A7101 ( 4.8A)
None
None
None
SAH  A7101 (-2.7A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 8
ASP D 163
ASP D 161
ILE D 132
TYR D 135
1.64A21.91
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_A_TOYA501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
PHE E 429
ASP E 428
ILE L  34
SER E 514
VAL E 512
1.58A20.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla HEAVY CHAIN
LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
ASP A 389
SER A 383
TYR B  32
GLU E 327
GLU C  61
1.76A20.30
None
DMS  A 905 (-3.9A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
PHE E 429
ASP E 428
ILE L  34
SER E 514
VAL E 512
1.66A20.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_A_TOYA501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
ASP E 428
ILE L  34
SER E 514
VAL E 512
TYR E 423
1.64A20.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yla LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
ASP E 428
ILE L  34
SER E 514
VAL E 512
TYR E 423
1.69A20.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_A_TOYA501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6ym0 LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
PHE E 429
ASP E 428
ILE L  34
SER E 514
VAL E 512
1.68A20.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_A_TOYA501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6ym0 LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
ASP E 428
ILE L  34
SER E 514
VAL E 512
TYR E 423
1.72A20.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6ym0 LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
PHE E 429
ASP E 428
ILE L  34
SER E 514
VAL E 512
1.75A20.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6ym0 LIGHT CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
ASP E 428
ILE L  34
SER E 514
VAL E 512
TYR E 423
1.76A20.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
PHE A 429
ASP A 428
ILE C  34
SER A 514
VAL A 512
1.66A19.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
ASP E 428
ILE L  34
SER E 514
VAL E 512
TYR E 423
1.70A19.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
ASP A 428
ILE C  34
SER A 514
VAL A 512
TYR A 423
1.70A19.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_B_TOYB501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
PHE E 429
ASP E 428
ILE L  34
SER E 514
VAL E 512
1.66A19.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_A_TOYA501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
PHE A 429
ASP A 428
ILE C  34
SER A 514
VAL A 512
1.59A19.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_A_TOYA501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
ASP E 428
ILE L  34
SER E 514
VAL E 512
TYR E 423
1.65A19.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_A_TOYA501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
ASP A 428
ILE C  34
SER A 514
VAL A 512
TYR A 423
1.65A19.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4JD6_A_TOYA501_1
(ENHANCED
INTRACELLULAR
SURVIVAL PROTEIN)		6yor IGG L CHAIN
SPIKE GLYCOPROTEIN
(Homo
sapiens;
SARS-CoV-2)		5 / 9
PHE E 429
ASP E 428
ILE L  34
SER E 514
VAL E 512
1.59A19.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 221
GLU A  83
ASP A 218
TYR A 217
1.76A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 477
TYR A 746
ASP A 481
ILE A 696
1.75A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		7btf NSP8
(SARS-CoV-2)		4 / 8
ASP B 163
ASP B 161
ILE B 132
TYR B 135
1.67A22.33
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 155
ASP A 153
ASP A 154
TYR A 149
1.79A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 477
TYR A 746
ASP A 481
ILE A 696
1.78A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 221
GLU A  83
ASP A 218
TYR A 217
1.77A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_B_TOYB501_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		7btf NSP12
(SARS-CoV-2)		5 / 9
SER A 564
SER A 561
ALA A 502
ASP A 684
THR A 565
1.46A11.60
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		7btf NSP12
(SARS-CoV-2)		5 / 10
SER A 564
SER A 561
ALA A 502
ASP A 684
THR A 565
1.48A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
ASP A 445
ILE A 450
ASP A 452
TYR A 455
1.77A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		7bv1 NSP12
(SARS-CoV-2)		5 / 10
SER A 564
SER A 561
ALA A 502
ASP A 684
THR A 565
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_B_TOYB501_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		7bv1 NSP12
(SARS-CoV-2)		5 / 9
SER A 564
SER A 561
ALA A 502
ASP A 684
THR A 565
1.46A11.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4EBK_A_TOYA301_1
(AMINOGLYCOSIDE
NUCLEOTIDYLTRANSFERA
SE)		7bv1 NSP12
(SARS-CoV-2)		5 / 9
GLU A 136
ASP A 161
GLU A 167
GLU A 796
ALA A 797
1.75A14.15
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ASP A 155
ASP A 153
ASP A 154
TYR A 149
1.53A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ASP A 235
TYR A 238
ILE A 466
TYR A 294
1.64A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		7bv2 NSP8
(SARS-CoV-2)		4 / 8
ASP B 163
ASP B 161
ILE B 132
TYR B 135
1.74A19.18
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ASP A 208
TYR A 237
ASP A  36
TYR A 732
1.75A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4XJE_A_TOYA202_1
(AADB)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ASP A 155
ASP A 153
ASP A 154
TYR A 149
1.66A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
5CFS_A_TOYA203_1
(AAD(2''),GENTAMICIN
2''-NUCLEOTIDYLTRANS
FERASE,GENTAMICIN
RESISTANCE PROTEIN)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ASP A 155
ASP A 154
GLU A 144
TYR A 149
1.79A12.74
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_B_TOYB501_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		7bv2 NSP12
(SARS-CoV-2)		5 / 9
SER A 564
SER A 561
ALA A 502
ASP A 684
THR A 565
1.74A11.46
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
1M4D_A_TOYA500_1
(AMINOGLYCOSIDE
2'-N-ACETYLTRANSFERA
SE)		7bv2 NSP12
(SARS-CoV-2)		5 / 10
SER A 564
SER A 561
ALA A 502
ASP A 684
THR A 565
1.76A
None